Mostrando 4 resultados de: 4
Publisher
Anales de Cirugia Cardiaca y Vascular(1)
Clinical Pharmacokinetics(1)
Frontiers in Psychology(1)
The Lancet Neurology(1)
A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
ArticleAbstract: The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) hPalabras claves:Clinical trials as topic, COGNITION, Down syndrome, Intellectual disabilities, TESDAD neurocognitive batteryAutores:Benejam B., Blanco L., Blehaut H., Catuara-Solarz S., Civit E., Cuenca-Royo A.M., de Sola S., del Hoyo L., Dierssen M., Espadaler J.M., Farré M., Freixas R., Hernandez G., Ivan Dueñas-Espín, PhD, Langohr K., Legout V., Peña-Casanova J., Principe A., Pujol J., Roca L., Rodríguez J., Sanchez-Benavides G., Sánchez-Gutiérrez J., Torre R.d.l., Trias K., Videla S., Xicota L.Fuentes:googlescopusVenous hypertension of the lower extremities (part II)
Conference ObjectAbstract:Palabras claves:Autores:Bonfill X., Capellà D., Ma José Martínez Zapata, Moreno R.M., Roche E., Romera J., Rosendo A., Videla S.Fuentes:scopusSafety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): A double-blind, randomised, placebo-controlled, phase 2 trial
ArticleAbstract: Background: Early cognitive intervention is the only routine therapeutic approach used for amelioratPalabras claves:Autores:Benejam B., Blanco-Hinojo L., Blehaut H., Catuara-Solarz S., Civit E., Cuenca-Royo A.M., de Sola S., del Hoyo L., Delabar J.M., Dierssen M., Espadaler J.M., Farré M., Fitó M., Freixas R., Hernandez G., Ivan Dueñas-Espín, PhD, Janel N., Langohr K., Legout V., Principe A., Pujol J., Roca L., Rodríguez J., Sanchez G., Sanchez-Benavides G., Sánchez-Gutiérrez J., Torre R.d.l., Trias K., Videla S., Xicota L.Fuentes:googlescopusPopulation Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement
ArticleAbstract: Background: Tranexamic acid (TXA), an antifibrinolytic drug, is usually administered intravenously;Palabras claves:Autores:Aguilera-Roig X., Baños Lapuente V., Cánovas Martínez E., Fernández Nuñez J.A., Font Gual A., González Osuna A., González Rodriguez J.C., Jordán-Sales M., Lamas C., Ma José Martínez Zapata, Pla-Junca F., Ramirez E., Rodríguez Prieto M., Rojas L.F., Valle M., Videla S.Fuentes:scopus